MDVN – Medivation, Inc., offers medical therapies to treat serious diseases like Cancer.
MDVN – Medivation, Inc.
|Fundamentals||Previously closed at||38.75|
|Analysts opinion||MDVN has a forward PE of 19.09, a profit margin of 25.95%. It is held mostly by institutional investors (95.5%). The stock slumped yesterday by 6% as it attracted the attention of Presidential candidate Bernie Sanders and a few other influential congressmen. Medivation manufactures “Xtandi”, a prostate cancer drug which has been highly priced in the U.S compared to other countries. The lawmakers would like to reduce the prices in U.S as well. MDVN’s partner, Astellas responded to that most patients with private insurance pay a minimum out of their pockets and the manufacturer provides Xtandi free of cost for many eligible uninsured or underinsured patients. However, analysts have a consensus “Buy” opinion for the stock with a price target of $47.|
|Sentiments||This year, being the election year in the U.S., the political environment tends to affect the stock price movements. MDVN’s sentiments have been bearish but investors expect the prices to rise once the focus shifts from the company. Investors may see this dip as an opportunity to buy the stock.|
|Social Media Pulse||The stock has 100% higher chatter than usual.|
XON – Interexon Corporation operates in the field of synthetic biology. It is into human therapeutics, Synthetic Immunology, Animal Sciences, Agricultural Biotech, and industrial Products.
XON – Interexon Corporation
|Fundamentals||Previously closed at||35.27|
|Analyst opinion||Interexon announced today that the pilot plant for its proprietary gas-to-liquids bioconversion platform is operational. The plant is dedicated to producing isobutanol, which is a fuel with many advantages over others. It is also on track for achieving the necessary yield to begin site-selection for its first commercial plant.|
|Sentiments||Due to the news, the sentiments for the stock are bullish for the medium to long term, with the investor expectation regarding its upcoming commercial plant in 2016. Many view XON as a great growth stock.|
|Social Media Pulse||The stock has 29% lower social chatter than usual.|
Disclaimer: This blog contains an aggregated view of analysts and opinions by the author. Do not consider this as financial advice. See http://stockal.com/legalities/